Halozyme CEO exercises 40k options, sells 40k shares
HALOZYME THERAPEUTICS, INC.
Rhea-AI Filing Summary
HALOZYME THERAPEUTICS, INC. President and CEO Helen Torley reported an exercise-and-sell transaction in company stock. On April 1–2, she exercised options to acquire a total of 40,000 shares of common stock at an exercise price of $12.0700 per share, from options with a ten-year term expiring in February 2027.
Over the same two days, she sold 40,000 shares of common stock in open-market trades at per-share prices including $65.3580, $65.7140, $64.0630 and $64.8870. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, she directly owned 767,780 shares of Halozyme common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 40,000 shares ($2.11M approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
Torley Helen
Role
PRESIDENT AND CEO
Sold
40,000 shs ($2.59M)
Approx. gross sale proceeds
$2.59M
Approx. exercise cost
$483K
Approx. pre-tax spread
$2.11M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock | 20,000 | $12.07 | $241K |
| Exercise | Common Stock | 20,000 | $12.07 | $241K |
| Sale | Common Stock | 15,800 | $64.063 | $1.01M |
| Sale | Common Stock | 4,200 | $64.887 | $273K |
| Exercise | Option to Purchase Common Stock | 20,000 | $12.07 | $241K |
| Exercise | Common Stock | 20,000 | $12.07 | $241K |
| Sale | Common Stock | 19,000 | $65.358 | $1.24M |
| Sale | Common Stock | 1,000 | $65.714 | $66K |
Holdings After Transaction:
Option to Purchase Common Stock — 111,923 contracts (Direct);
Common Stock — 767,780 shares (Direct)
Footnotes (6)
- F1. The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
- F2. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.650 to $65.640. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. The shares were sold at prices ranging from $65.660 to $65.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. The shares were sold at prices ranging from $63.650 to $64.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. Represents a weighted average sales price per share. The shares were sold at prices ranging from $64.660 to $65.380. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.
Key Figures
Options exercised: 40,000 shares
Shares sold: 40,000 shares
Option exercise price: $12.0700 per share
+3 more
6 metrics
Options exercised
40,000 shares
Total underlying shares from option exercises on April 1–2, 2026
Shares sold
40,000 shares
Aggregate common shares sold in open-market trades on April 1–2, 2026
Option exercise price
$12.0700 per share
Exercise price for options to purchase Halozyme common stock
Post-transaction holdings
767,780 shares
Common shares directly owned by Helen Torley after final sale
Sale tranche
19,000 shares at $65.3580
One reported open-market sale of Halozyme common stock on April 1, 2026
Option term
10 years, expiring February 2027
Ten-year stock option term ending in February 2027 per footnote
Key Terms
Rule 10b5-1, weighted average sales price per share, stock options, ten-year term, +1 more
5 terms
Rule 10b5-1 regulatory
"written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
stock options financial
"shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
ten-year term financial
"exercise of stock options with a ten-year term expiring in February 2027"
Form 4 regulatory
"The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Halozyme (HALO) CEO Helen Torley report?
Helen Torley reported an exercise-and-sell transaction in Halozyme shares. She exercised options to acquire 40,000 shares at $12.0700 per share, then sold 40,000 common shares in open-market trades at various prices in the mid-$60 range under a Rule 10b5-1 trading plan.
What stock options did Helen Torley exercise in this Halozyme (HALO) Form 4?
She exercised stock options covering 40,000 Halozyme shares. The options carried an exercise price of $12.0700 per share and a ten-year term, with expiration in February 2027, reflecting grants originally made on February 22, 2017 and vesting over a four-year period.
What is notable about the options exercised in Helen Torley’s Halozyme (HALO) Form 4?
The exercised options were nearing the end of a ten-year term. The filing notes that the sales involved shares acquired from exercising stock options with a ten-year term expiring in February 2027, originally granted on February 22, 2017 with standard four-year vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
